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Abstract
Background: Dyslipidemia is an important independent modifiable risk factor for cardiovascular disease. The aim of
this study was to explore the current prevalence, awareness, treatment and control of dyslipidemia and its associated
influence factors in northeast China.
Methods: In this population-based cross-sectional study, we adopted a multi-stage, stratified sampling method to obtain
a representative sample of 4052 permanent residents aged 40 years and over from different urban and rural regions in
Dehui City of Jilin Province. All subjects completed a questionnaire and were examined for risk factors. Continuous data
were presented as means ± standard deviations (SD) and compared using the Student’s t-test. Categorical variables were
presented as proportions and compared using the Rao-Scott-χ2 test in different subgroups. The associated influence
factors for the prevalence, awareness, treatment and control of dyslipidemia were evaluated through multivariate logistic
regression.
Results: The prevalence of dyslipidemia was 62.1% overall, with 33.5, 43.9, 0.6, and 8.8% for high total cholesterol,
triglyceride, low-density lipoprotein cholesterol, and low high-density lipoprotein cholesterol, respectively. Among
those with dyslipidemia, the proportion of subjects who were aware, treated, and controlled was 14.4, 33.9, and 19.9%,
respectively. Overweight or obesity (OR = 2.156; 95% CI: 1.863, 2.533), hypertension (OR = 1.643; 95% CI: 1.425, 1.893), or
diabetes mellitus (OR = 2.173; 95% CI: 1.661, 2.844) increased the prevalence of dyslipidemia, also these participants
were more likely to be aware of their condition, however, this did not increase the likelihood of treatment and control.
Living in urban areas and higher education level also increased the awareness of dyslipidemia. Personal history of
coronary heart disease was the strongest influence factors associated with better awareness, treatment and control of
dyslipidemia. Overweight or obesity (OR = 0.404; 95% CI: 0.235, 0.695) and lack of exercise (OR = 0.423; 95% CI: 0.215, 0.
830) were associated with poor control of dyslipidemia.
Conclusion: The prevalence of dyslipidemia among adults aged 40 years and over in northeast China was high,
however, the awareness, treatment, and control of dyslipidemia was measured at far from desirable levels. Renewed
efforts taking influence factors into account are needed to improve the current unsatisfactory condition.
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Background
Coronary heart disease and cerebrovascular disease, as
two major types of cardiovascular disease (CVD), were
ranked as the top two caused of premature death and
disability-adjusted life-years (DALYs) worldwide [1, 2],
and contributed considerably to the increasing health-
care expenditures, especially in low- and middle-income
countries, as well as in China [3, 4]. With the rapid eco-
nomic expansion and increasing average life expectancy,
CVD has become the leading cause of death in China,
and its morbidity and mortality has been increasing
since the late 1980s. Currently, CVD accounts for up to
40% of all deaths in both urban and rural populations in
China [5].
On a more positive note, a considerable proportion of
this morbidity and mortality could be prevented through
early intervention of cardiovascular risk factors, such as
low physical activity, tobacco use, dyslipidemia, hyper-
tension, diabetes, etc.[6, 7], in which dyslipidemia plays
an important role in the formation and development of
atherosclerosis, and its association with risk of CVD is
indisputable [8–10]. Therefore, early screening and
effective lipid management may substantially reduce the
burden of CVD and provide great social value [3].
With the improved standard of living, unhealthy diet-
ary patterns and sedentary lifestyles have increased, and
the age-standardized prevalence rate of dyslipidemia has
been gradually increasing [3, 11, 12]. Moreover, this rate
varies by region due to different climatic environments,
diets, and lifestyles [13]. The latest data from Jilin Prov-
ince in northeast China reported that the awareness,
treatment, and control rate of dyslipidemia were 11.6,
8.4, and 34.8%, respectively, in 2012 [14]. However, this
data did not contain the prevalence rates of dyslipidemia
or details regarding the subtypes of lipid disorders (high
serum total cholesterol, triglycerides, low-density lipo-
protein cholesterol, and low high-density lipoprotein
cholesterol). The 2015–16 Stroke Screening and Preven-
tion Program of the National Health and Family Plan-
ning Commission of China Study includes these data
and remains the latest cross-sectional survey in northeast
China. Based on this survey database, we analyzed the
current prevalence, awareness, treatment, and control of
dyslipidemia and its associated influence factors in Jilin
Province, northeast China.
Methods
Data source and study population
This survey was conducted from January to March 2016
as part of the Stroke Screening and Prevention Program
of the National Health and Family Planning Commission
of China [15]. It was a population-based cross-sectional
study designed to provide timely and reliable data for
the prevalence of stroke and associated factors in adults
over 40 years of age in northeast China, and it was
supervised by the Chinese National Center for Stroke
Care Quality Control and Management. This survey
adopts the multistage stratified random cluster sampling
method to select representative samples of the general
population over 40 years who had lived in Dehui City
for more than 6 months and voluntarily participated in
the survey. In the first stage, 30 villages and 10 towns
were selected from 308 villages (rural) and 14 towns
(urban), respectively, in Dehui city. In the second stage,
cluster sampling was used in the areas selected above.
The study was approved by the Human Ethics and
Research Ethics committees of the First Hospital of Jilin
University (Approval Number: 2015-R-250). Written
informed consent was obtained from all participants in
the survey.
Sampling size
The targeted population for the Stroke Screening and
Prevention Program of the National Health and Family
Planning Commission of China 2015–16 were adults
aged 40 years and over, and there were 335,490 residents
over 40 years in Dehui City, according to the main data
bulletin of the 6th National Population Census in 2010
(announced by the Statistical Bureau of Jilin Province).
The expected sample size was 3355, which was 1% of
the targeted population. Non-response rate was esti-
mated as 20%, so the planned sample size was 4026; a
final number of 4100 residents participated in the sur-
vey. For the purpose of the present analysis, 48 subjects
were excluded due to missing values. Finally, a total of
4052 people were included in the present analysis.
Data collection and measurement
All participants completed a structured pre-coded ques-
tionnaire designed by the National Health Development
Planning Commission for Stroke Screening and Preven-
tion Engineering, including demographic details (e.g.,
gender, age, residence, and education level), personal
lifestyle (e.g., smoking, drinking, exercise habits, and diet
structure), personal and family medical history of stroke
and chronic diseases (i.e., hypertension, diabetes mellitus,
dyslipidemia, and atrial fibrillation), and anthropometric
measurements (e.g., height, weight, resting blood pressure,
neck, waist, and hip circumference). Height and weight
were measured according to standardized protocol and
techniques, with the participants wearing clothes but no
shoes. Blood pressure was measured by trained profes-
sionals using an electronic sphygmomanometer (OMRON
HEM-7200), and each participant was measured twice,
resting for at least 20 min before measurements were
taken. We took the average of these readings. In addition,
a blood sample was drawn from the participant’s antecubi-
tal vein for measuring fasting blood glucose (FBG), total
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cholesterol (TC), triglycerides (TGs), low-density lipopro-
tein cholesterol (LDL-C), and high-density lipoprotein
cholesterol (HDL-C), and the sample was uniformly
measured by the Changchun Kingmed Center for Clinical
Laboratory Co., Ltd. All participants underwent electro-
cardiograms for the detection of atrial fibrillation.
Assessment criteria
Dyslipidemia [16] was defined as using an antilipidemic
medication or having one or more of the following in
the field survey: TC ≥ 5.18 mmol/L, TGs ≥ 1.70 mmol/L,
LDL-C ≥ 3.37 mmol/L, and. HDL-C < 1.04 mmol/L.
Dyslipidemia awareness was defined as self-report of
any previous diagnosis of dyslipidemia by a healthcare
professional. The treatment rate of dyslipidemia was de-
fined as the self-reported use of lipid-lowering drugs
among participants who were aware of dyslipidemia.
The control rate of dyslipidemia refers to the proportion
among those treated for dyslipidemia who reach the
lipid standard: TG < 1.70 mmol/L, TC < 5.18 mmol/L,
HDL-C ≥ 1.04 mmol/L, and LDL-C < 3.37 mmol/L.
Statistical analysis
Complex weighted computation was used to make the
sample more accurately representative of the population
in Dehui City of the Jilin Province by post-stratification
adjustment according to the following factors: age, resi-
dence, and gender groups, according to the standard
population in the 6th national general investigation in
Dehui City of the Jilin Province. Continuous data are
presented as means ± standard deviations (SD) and com-
pared using the Student’s t-test. Categorical variables
were presented as proportions and compared using the
Rao-Scott-χ2 test in different subgroups. Finally, the as-
sociated influence factors for the prevalence, awareness,
treatment, and control of dyslipidemia were analyzed
through multivariate logistic regression. All statistical
analyses were performed using the complex samples
function of IBM SPSS 17.0 (SPSS Inc., New York, NY,
USA). Statistical significance was set at p < 0.05.
Results
Characteristics of the study sample
The study’s 4052 participants included 1619 men (mean
age was 55.72 ± 9.43 years) and 2433 women (mean age
was 54.27 ± 9.17 years). The number of cases repre-
sented by urban participants was 2067 (51.0%) and that
of rural participants was 1985 (49.0%).
Demographic and clinical characteristics of participants
enrolled in this cross-sectional population-based survey
according to dyslipidemia status are shown in Table 1.
Compared with the non-dyslipidemia group, we found
that the dyslipidemia group had a higher prevalence of
hypertension, diabetes mellitus, overweight or obesity, lack
of exercise, personal and family history of stroke and cor-
onary heart disease, family history of dyslipidemia, and
central obesity (p < 0.001, except p < 0.05 for family history
of stroke). In addition to this, the dyslipidemia group was
usually older and had higher systolic blood pressure and
diastolic blood pressure, higher fasting blood-glucose, and
higher neck, waist, and hip circumferences than those of
the non-dyslipidemia group (all p < 0.001).
Prevalence of different types of dyslipidemia
As shown in Table 2, the overall adjusted prevalence of
dyslipidemia was 62.1% (95% CI: 60.3–63.9%). It first in-
creased, and then decreased with age (p < 0.05), and the
peak prevalence appeared in the 60–69 year age group,
and the same trend occurred in high total cholesterol
measurements (p < 0.001). The prevalence of dyslipid-
emia showed no statistically significant difference be-
tween males and females (61.3% vs. 62.9%, p = 0.383),
but that of low high-density lipoprotein cholesterol was
significantly higher in males than females (11.1% vs.
6.4%, p < 0.001), yet the opposite was true for high total
cholesterol (31.6% vs. 35.5%, p = 0.031). The adjusted
prevalence rates of high total cholesterol, triglycerides,
low-density lipoprotein, and low high-density lipoprotein
were 33.5, 43.9, 0.6, and 8.8%, respectively. Compared
with the rural areas, participants in urban areas had a
higher prevalence of high triglyceride, low high-density
lipoprotein, and dyslipidemia (all p < 0.001). The preva-
lence of high total cholesterol decreased with education
level (p < 0.001); however, that of low high-density lipopro-
tein showed the opposite trend (p < 0.001). With regard to
body weight, the prevalence rates of dyslipidemia, high
total cholesterol, triglycerides, low-density lipoprotein, and
low high-density lipoprotein cholesterol were significant
higher among those overweight or obesity than in others
(p < 0.001, except p < 0.05 for high low-density lipopro-
tein). The prevalence of any types of dyslipidemia was not
significantly associated with smoking or alcohol consump-
tion status (all p > 0.05). In addition, subjects who have
personal or family history of stroke and coronary heart dis-
ease, or family history of dyslipidemia had higher preva-
lence of dyslipidemia than those without any history of
these conditions (all p < 0.05); and participants with family
history of stroke were more likely to suffer from high low-
density lipoprotein cholesterol compared to those without
family history of stroke (1.5% vs. 0.1%, p < 0.001). Whereas,
participants with family history of coronary heart disease
or dyslipidemia had higher levels of prevalence of high
total cholesterol and triglyceride as against those without
any history of these conditions (p < 0.05).
Awareness, treatment, and control of dyslipidemia
The overall awareness, treatment, and control rates of
dyslipidemia were 14.4% (95% CI: 12.9–16.0%), 33.9%
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Age (years) 55.52 ± 9.15 53.68 ± 9.45 6.104 <0.001
Gender (Male) 1027 (40.0) 592 (39.9) 0.992
Residence 0.037
Urban, n (%) 1343 (52.3) 724 (48.9)
Rural, n (%) 1227 (47.7) 758 (51.1)
Education, n (%) 0.163
Primary school and below 934 (36.3) 512 (34.5)
Junior middle school 1070 (41.6) 626 (42.2)
Senior middle school 341 (13.3) 196 (13.2)
College and above 225 (8.8) 148 (10.0)
aHypertension, n (%) 1668 (64.9) 667 (45.0) <0.001
bDiabetes mellitus, n (%) 366 (14.2) 75 (5.1) <0.001
cOverweight or obesity, n (%) 962 (37.4) 277 (18.7) <0.001
dLack of exercise, n (%) 623 (24.2) 279 (18.8) <0.001
ePersonal history of stroke, n (%) 219 (8.5) 73 (4.9) <0.001
fFamily history of stroke, n (%) 921 (35.8) 476 (32.1) 0.016
gPersonal history of coronary heart disease, n (%) 207 (8.1) 65 (4.4) <0.001
hFamily history of coronary heart disease, n (%) 694 (27.0) 317 (21.4) <0.001
iFamily history of dyslipidemia, n (%) 498 (19.4) 126 (8.5) <0.001
BMI (kg/m2), n (%) <0.001
BMI < 18.0 25 (1.0) 39 (2.6)
18≤ BMI < 24.0 944 (36.7) 884 (59.6)
24≤ BMI < 26.0 639 (24.9) 282 (19.0)
26≤ BMI < 28.0 497 (19.3) 154 (10.4)
BMI≥ 28.0 465 (18.1) 123 (8.3)
jCentral obesity, n (%) 1516 (59.0) 528 (35.6) <0.001
SBP (mmHg) 144.16 ± 21.61 135.58 ± 20.73 12.485 <0.001
DBP (mmHg) 90.46 ± 11.91 85.86 ± 11.03 12.416 <0.001
TG CHOHDLLDL (mmol/L)
TC 5.77 ± 1.21 4.75 ± 0.68 34.294 <0.001
TG 2.61 ± 2.01 1.12 ± 0.31 36.703 <0.001
LDL-C 2.16 ± 0.77 2.09 ± 0.85 2.2652 0.008
HDL-C 1.22 ± 0.26 1.31 ± 0.20 −11.132 <0.001
FBG (mmol/L) 5.52 ± 1.88 4.98 ± 1.08 11.640 <0.001
Neck circumference (cm) 34.71 ± 3.37 33.40 ± 2.94 12.936 <0.001
Waist circumference (cm) 87.51 ± 8.86 82.27 ± 8.99 18.035 <0.001
Hip circumference (cm) 97.77 ± 8.25 93.50 ± 8.36 15.737 <0.001
Fruit consumption, n (%) 0.998
≥ 5d/w 2273 (88.4) 1307 (88.2)
3-4d/w 223 (8.7) 136 (9.2)
≤ 2d/w 74 (2.9) 39 (2.6)
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(95% CI: 28.5–39.8%), and 19.9% (95% CI: 15.5–25.2%),
respectively (shown in Table 3).
Awareness of dyslipidemia
The awareness of dyslipidemia generally increased with
increasing age (p = 0.007), with the last age group 70–
having the highest level of awareness, 18.9% (95% CI:
13.3–26.0%); additionally, those living in the urban areas,
with a high educational level, and those who were lack
of exercise, overweight or obesity, with personal history
of stroke or coronary heart disease, and family history of
coronary heart disease usually had a higher rate of
awareness than those living in the rural areas, with a low
educational level, and those who got enough exercise,
had a relatively normal body mass index, without personal
history of stroke or coronary heart disease, or family his-
tory of coronary heart disease (all p < 0.05). However, the
awareness of dyslipidemia was not significantly associated
with gender (p = 0.287), smoking (p = 0.236) or alcohol
consumption status (p = 0.185).
Treatment of dyslipidemia
Among participants who were aware of dyslipidemia,
those with family history of coronary heart disease were
more likely to treat their dyslipidemia than those with-
out family history of coronary heart disease (p = 0.030).
In the present study, treatment of dyslipidemia was not
found to be significantly associated with age (p = 0.763),
gender (p = 0.320), residential area (p = 0.237), education
level (p = 0.225), exercise habits (p = 0.128), smoking
(p = 0.245) or alcohol consumption status (p = 0.282),
BMI (p = 0.476), personal history of stroke (p = 0.147)
or coronary heart disease (p = 0.080), or family history
of stroke (p = 0.122) or dyslipidemia (p = 0.224).
Control of dyslipidemia
Among dyslipidemia patients using lipid-lowering drugs,
participants with regular exercise were more likely to
have their dyslipidemia controlled than those who were
lack of exercise (23.4% vs. 10.2%, p = 0.013). Besides,
overweight or obesity (BMI ≥ 26 kg/m2) was associated
with a lower level of dyslipidemia control than those
with BMI <26 kg/m2 (p = 0.006).
Factors associated with the prevalence, awareness,
treatment, and control of dyslipidemia
Multiple logistic regression analysis (Table 4) suggests
that the prevalence of dyslipidemia was significantly as-
sociated with increasing age; and participants living in
urban regions (OR = 1.339; 95% CI: 1.161, 1.543) were
more inclined to suffer from dyslipidemia. Overweight
or obesity (OR = 2.156; 95% CI: 1.863, 2.533) and lack of
exercise (OR = 1.212; 95% CI: 1.021, 1.439) were associ-
ated with an increased prevalence of dyslipidemia. Sub-
jects with hypertension (OR = 1.643; 95% CI: 1.425,
1.893), or diabetes mellitus (OR = 2.173; 95% CI: 1.661,
2.844) were more likely to have dyslipidemia. In
addition, participants with personal (OR = 1.365; 95% CI:
1.006, 1.851) or family history of coronary heart disease
(OR = 1.182; 95% CI: 1.004, 1.391), or family history of
Table 1 Characteristics of participants according to dyslipidemia status (Continued)
kSmoker 0.231
Yes 1304 (50.7) 723 (48.8)
No 1266 (49.3) 759 (51.2)
Alcohol consumption, n (%) 0.887
Never 1878 (73.1) 1100 (74.2)
Moderate drinking 399 (15.5) 242 (16.3)
Excessive drinking 293 (11.4) 140 (9.4)
Abbreviations: BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein
cholesterol, HDL-C high-density lipoprotein cholesterol; FBG, fasting blood-glucose
aHypertension was defined as self-reported history and/or the use of antihypertensive medication in the past 2 weeks, or the average of two times resting systolic
blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg in the field survey
bDiabetes mellitus was defined as the use of insulin and/or oral hypoglycemic medications or a self-reported history of diabetes or FBG ≥ 7.0 mmol/L in the
field survey
cOverweight or obesity was defined as BMI ≥ 26 kg/m2. Body mass index (BMI) was calculated as weight (kg) divided by height squared (m2)
dLack of exercise was defined as physical exercise < 3 times a week for < 30 min each time, and this included industrial and agricultural labor
eRespondents with a history of stroke were asked to provide their outpatient or inpatient medical records, and the diagnostic criteria met the WHO criteria
for stroke
fFamily history of stroke was restricted to immediate family members
gRespondents with a history of coronary heart disease were asked to provide their outpatient or inpatient medical records, and the diagnostic criteria met the
WHO criteria for coronary heart disease
hFamily history of coronary heart disease was restricted to immediate family members
iFamily history of dyslipidemia was restricted to immediate family members
jCentral Obesity was defined by waist circumference >90 cm for male and >80 cm for female
kA smoker was defined as one who reported having smoked one or more cigarettes or was passively exposed to tobacco smoke every day in general for more
than 6 consecutive months
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Table 2 Prevalence of different types of dyslipidemia in northeast China
Category Subcategory H-TC H-TG H-LDL L-HDL Dyslipidemia
Total 33.5(31.8–35.3) 43.9(42.0–45.7) 0.6(0.3–1.0) 8.8(7.8–9.8) 62.1(60.3–63.9)
Age 40–49 27.3(24.4–30.4) 44.2(40.9–47.5) 0.6(0.2–1.6) 9.2(7.5–11.2) 58.6(55.3–61.8)
50–59 37.3(34.5–40.2) 45.5(42.6–48.5) 0.5(0.2–1.4) 8.6(7.1–10.3) 64.4(61.4–67.2)
60–69 38.5(35.3–41.8) 44.3(41.0–47.6) 0.3(0.1–1.1) 7.9(6.4–9.7) 65.7(62.4–68.9)
70– 38.2(32.1–44.7) 37.2(31.3–43.6) 0.8(0.2–3.4) 9.1(6.3–13.0) 63.3(56.8–69.3)
p value <0.001 0.092 0.863 0.792 0.014
Gender Male 31.6(28.9–34.3) 42.2(39.4–45.1) 0.7(0.4–1.5) 11.1(9.5–12.9) 61.3(58.5–64.1)
Female 35.5(33.2–37.8) 45.6(43.2–47.9) 0.4(0.1–0.9) 6.4(5.4–7.6) 62.9(60.6–65.2)
p value 0.031 0.075 0.236 <0.001 0.383
Residence Urban 28.8(26.8–30.9) 49.6(47.3–51.8) 0.2(0.1–0.7) 15.6(14.0–17.4) 66.4(64.2–68.4)
Rural 35.1(32.9–37.4) 42.0(39.6–44.3) 0.7(0.4–1.2) 6.5(5.4–7.8) 60.7(58.3–63.0)
p value <0.001 <0.001 0.089 <0.001 <0.001
Education Primary school and below 36.8(34.1–39.6) 43.7(40.9–46.6) 0.6(0.3–1.2) 6.9(5.6–8.6) 62.9(60.0–65.6)
Junior middle school 31.3(28.6–34.2) 43.4(40.5–46.4) 0.6(0.2–1.6) 9.6(8.1–11.3) 60.5(57.5–63.4)
Senior middle school 30.7(26.3–35.5) 44.7(39.9–49.7) 0.2(0.0–1.7) 12.6(9.6–16.3) 64.2(59.3–68.9)
College and above 23.6(19.1–28.9) 47.7(42.1–53.4) 0.4(0.1–3.1) 13.6(10.3–17.8) 63.9(58.5–69.0)
p value <0.001 0.685 0.878 <0.001 0.391
Lack of exercise Yes 33.9(30.1–38.0) 49.9(45.8–54.0) 0.1(0.0–0.4) 12.3(10.1–14.8) 67.4(63.3–71.2)
No 33.4(31.5–35.4) 42.6(40.5–44.6) 0.7(0.4–1.2) 8.0(7.0–9.2) 61.0(58.9–63.0)
p value 0.839 0.002 0.003 <0.001 0.006
Smoking Yes 34.1(31.7–36.5) 44.4(41.9–46.9) 0.5(0.3–1.1) 8.4(7.1–9.8) 62.4(59.9–64.8)
No 32.7(30.1–35.3) 43.1(40.4–45.8) 0.6(0.3–1.5) 9.4(8.0–11.1) 61.7(58.9–64.3)
p value 0.433 0.478 0.787 0.314 0.691
Overweight or obesity Yes 38.5(35.3–41.8) 62.0(58.7–65.2) 1.1(0.5–2.4) 13.6(11.4–16.0) 77.2(74.3–79.9)
No 31.3(29.2–33.4) 35.7(33.6–37.9) 0.3(0.1–0.7) 6.6(5.7–7.7) 55.3(53.0–63.7)
p value <0.001 <0.001 0.012 <0.001 <0.001
Alcohol consumption Never 33.7(31.7–35.8) 43.9(41.8–46.0) 0.5(0.2–1.0) 8.7(7.6–9.9) 62.0(59.9–64.1)
Moderate drinking 31.4(27.2–35.9) 43.5(39.0–48.2) 0.7(0.2–2.4) 9.4(7.1–12.4) 61.2(56.6–65.7)
Excessive drinking 35.7(30.6–41.2) 44.4(38.9–50.0) 0.6(0.2–2.6) 8.4(6.0–11.6) 64.1(58.5–69.4)
p value 0.438 0.973 0.859 0.814 0.712
Personal history of stroke Yes 38.5(32.2–45.3) 50.9(44.1–57.6) 0.1(0.0–0.8) 11.5(7.9–16.5) 73.5(67.1–79.0)
No 33.1(31.3–35.0) 43.3(41.4–45.3) 0.6(0.3–1.1) 8.6(7.6–9.6) 61.2(59.3–63.1)
p value 0.109 0.035 0.078 0.137 <0.001
Family history of stroke Yes 35.1(32.1–38.2) 46.1(42.9–49.3) 1.5(0.8–2.7) 10.0(8.2–12.1) 66.0(62.9–68.9)
No 32.7(30.6–34.9) 42.8(40.5–45.0) 0.1(0.0–0.4) 8.2(7.1–9.4) 60.2(57.9–62.4)
p value 0.221 0.098 <0.001 0.099 0.003
Personal history of
coronary heart disease
Yes 27.8(22.3–34.1) 50.7(43.6–57.7) 0.3(0.0–2.4) 12.1(8.4–17.2) 69.6(62.4–76.0)
No 33.9(32.1–35.8) 43.4(41.5–45.3) 0.6(0.3–1.0) 8.5(7.6–9.6) 61.6(59.7–63.5)
p value 0.066 0.051 0.618 0.075 0.035
Family history of coronary
heart disease
Yes 38.2(34.6–41.9) 47.2(43.4–50.9) 0.8(0.3–2.3) 8.8(6.9–11.2) 67.6(64.0–71.1)
No 32.0(30.1–34.1) 42.8(40.7–45.0) 0.5(0.2–0.9) 8.8(7.7–10.0) 60.4(58.2–62.5)
p value 0.003 0.049 0.427 0.938 0.001
Family history of dyslipidemia Yes 47.3(42.8–51.8) 57.5(53.0–61.9) 1.2(0.5–3.1) 10.0(7.6–13.1) 79.8(75.9–83.1)
No 30.3(28.4–32.2) 40.7(38.7–42.7) 0.4(0.2–0.8) 8.5(7.5–9.6) 57.9(55.9–60.0)
p value <0.001 <0.001 0.054 0.290 <0.001
Abbreviations: H-TC high total cholesterol, H-TG high triglyceride, H-LDL high low-density lipoprotein cholesterol, L-HDL low high-density lipoprotein cholesterol
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Table 3 Awareness, treatment and control of dyslipidemia
Category Subcategory Dyslipidemia
Awareness Treatment Control
Total 14.4(12.9–16.0) 33.9(28.5–39.8) 19.9(15.5–25.2)
Age 40–49 11.6(9.2–14.6) 35.3(24.4–48.0) 17.7(10.0–29.2)
50–59 13.7(11.5–16.3) 29.8(22.2–38.7) 14.6(9.0–22.7)
60–69 18.5(15.6–21.8) 34.5(26.3–43.8) 21.8(15.0–30.6)
70– 18.9(13.3–26.0) 38.7(22.7–57.6) 33.1(18.3–52.1)
p value 0.007 0.763 0.123
Gender Male 15.2(12.9–17.9) 31.2(23.4–40.1) 22.2(15.5–30.6)
Female 13.5(11.7–15.6) 36.9(29.8–44.6) 17.4(12.4–23.9)
p value 0.287 0.320 0.314
Residence Urban 19.7(17.5–22.0) 30.1(24.6–36.2) 15.9(11.7–21.2)
Rural 12.4(10.5–14.5) 36.1(28.3–44.7) 22.3(15.9–30.2)
p value <0.001 0.237 0.130
Education Primary school and below 12.0(9.9–14.5) 28.9(20.7–38.8) 18.8(11.8–28.6)
Junior middle school 14.4(12.0–17.2) 39.6(30.5–49.4) 21.3(14.4–30.4)
Senior middle school 22.3(17.5–27.8) 37.4(25.2–51.6) 17.0(9.6–28.4)
College and above 23.2(17.9–29.6) 26.1(15.4–40.7) 23.4(13.1–38.3)
p value <0.001 0.225 0.847
Lack of exercise Yes 19.8(16.1–24.1) 27.0(18.5–37.5) 10.2(5.2–19.0)
No 13.1(11.5–14.8) 36.4(29.9–43.4) 23.4(17.9–30.0)
p value 0.001 0.128 0.013
Smoking Yes 13.6(11.7–15.9) 31.2(23.9–39.5) 18.8(12.9–26.6)
No 15.5(13.4–18.0) 37.8(30.2–46.0) 21.4(15.6–28.8)
p value 0.236 0.245 0.589
Overweight or obesity Yes 20.8(17.9–24.0) 32.1(24.9–40.3) 13.7(8.8–20.7)
No 10.3(8.8–12.1) 36.2(28.4–44.7) 27.7(20.6–36.1)
p value <0.001 0.476 0.006
Alcohol consumption Never 14.4(12.6–16.3) 37.0(30.6–44.0) 19.7(14.7–25.8)
Moderate drinking 12.1(8.8–16.5) 30.2(16.9–48.0) 27.2(14.8–44.4)
Excessive drinking 17.7(13.5–23.0) 24.1(13.6–39.0) 13.3(5.6–28.6)
p value 0.185 0.282 0.329
Personal history of stroke Yes 27.4(21.1–34.9) 43.3(29.7–58.0) 18.3(9.2–33.1)
No 13.1(11.6–14.8) 32.1(26.3–38.5) 20.2(15.4–26.0)
p value <0.001 0.147 0.777
Family history of stroke Yes 15.1(12.6–17.9) 39.6(30.6–49.4) 20.1(13.4–28.8)
No 14.0(12.1–16.0) 30.5(24.1–37.8) 19.8(14.3–26.7)
p value 0.505 0.122 0.960
Personal history of coronary heart disease Yes 33.2(26.0–41.2) 44.8(31.7–58.7) 29.4(18.2–43.9)
No 12.9(11.4–14.6) 31.8(25.9–38.3) 18.0(13.4–23.8)
p value <0.001 0.080 0.078
Family history of coronary heart disease Yes 17.6(14.5–21.2) 43.0(33.0–53.6) 23.7(16.0–33.7)
No 13.2(11.6–15.1) 29.6(23.5–36.5) 18.1(13.0–24.6)
p value 0.018 0.030 0.283
Family history of dyslipidemia Yes 15.0(11.8–18.9) 40.3(28.2–53.9) 17.5(9.7–29.5)
No 14.2(12.5–16.0) 31.7(26.0–37.9) 20.7(15.7–26.8)
p value 0.683 0.224 0.595
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dyslipidemia (OR = 2.135; 95% CI: 1.710, 2.666) were
more likely to have dyslipidemia compared to those
without any history of these conditions.
As shown in Table 5, participants living in urban areas
(OR = 1.368; 95% CI: 1.021, 1.834) were more likely to
be aware of their dyslipidemia condition than those
living in the rural areas. Subjects with education level of
senior middle school (OR = 1.963; 95% CI: 1.305, 2.953)
or college and above (OR = 2.325; 95% CI: 1.447, 3.734)
tended to be more aware of their dyslipidemia condition
than those with education level of primary school and
below. Participants overweight or obesity (OR = 1.881; 95%
CI: 1.499, 2.359), or those with hypertension (OR= 1.751;
95% CI: 1.339, 2.289) or diabetes mellitus (OR = 1.727;
95% CI: 1.305, 2.286) were more inclined to be aware
of their dyslipidemia condition. In addition, having a
personal history of coronary heart disease (OR = 2.595;
95% CI: 1.864, 3.613) or stroke (OR = 2.176; 95% CI:
1.552, 3.051) increased the tendency of dyslipidemia
awareness.
Table 6 indicates that subjects with a personal history
of coronary heart disease (OR = 2.021; 95% CI: 1.183,
3.453) or stroke (OR = 1.743; 95% CI: 1.002, 3.032) were
more inclined to receive treatment for dyslipidemia than
those without these conditions.
Table 7 illustrates that overweight or obesity (OR =
0.404; 95% CI: 0.235, 0.695) and lack of exercise (OR
= 0.423; 95% CI: 0.215, 0.830) were associated with
poor control of dyslipidemia; and subjects with per-
sonal history of coronary heart disease (OR = 2.065;
95% CI: 1.083, 3.905) were more likely to control
their serum lipids at normal levels.
Discussion
In this population-based cross-sectional epidemiological
study, we have identified a high prevalence of dyslipid-
emia among adults aged 40 years and over in northeast
China, especially in urban areas. Additionally, we found
that high triglyceride was the most prevalent type of dys-
lipidemia in northeast China, followed by high total
cholesterol. However, the awareness, treatment, and con-
trol rate of dyslipidemia were at far from desirable levels.
Increasing age, living in urban regions and family history
of dyslipidemia were associated with higher risk of
dyslipidemia. But beyond that, participants with under-
lying chronic diseases, such as overweight or obesity,
Table 4 Multivariate logistic regression analyses on influence factors for prevalence of dyslipidemia
Category Subcategory Fully adjusted OR (95% CI) Wald χ2 value p value
Age(years) 40–49 1.00 (Referent)
50–59 1.506(1.277–1.776) 23.739 <0.001
60–69 1.524(1.267–1.834) 19.933 <0.001
70– 1.335 (1.006–1.772) 3.994 0.046
Gender Female 1.00 (Referent)
Male 0.914(0.795–1.052) 1.567 0.211
Residence Rural 1.00 (Referent)
Urban 1.339(1.161–1.543) 16.184 <0.001
Overweight or obesity No 1.00 (Referent)
Yes 2.156(1.836–2.533) 87.602 <0.001
Lack of exercise No 1.00 (Referent)
Yes 1.212(1.021–1.439) 4.810 0.028
Hypertension No 1.00 (Referent)
Have 1.643(1.425–1.893) 47.023 <0.001
Diabetes mellitus No 1.00 (Referent)
Have 2.173(1.661–2.844) 32.006 <0.001
Personal history of coronary heart disease No 1.00 (Referent)
Yes 1.365(1.006–1.851) 3.989 0.046
Family history of coronary heart disease No 1.00 (Referent)
Yes 1.182(1.004–1.391) 4.052 0.044
Family history of dyslipidemia No 1.00 (Referent)
Have 2.135(1.710–2.666) 44.886 <0.001
Method: Enter: Age, Gender, Residence; Forward-Conditional: Overweight or obesity, Hypertension, Diabetes mellitus, Lack of exercise, Personal history of stroke,
Personal history of coronary heart disease, Family history of coronary heart disease, Family history of dyslipidemia
Abbreviations: OR odds ratio, CI confidence interval
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Table 5 Multivariate logistic regression analyses on influence factors for awareness of dyslipidemia
Category Subcategory Fully adjusted OR (95% CI) Wald χ2 value p value
Age(years) 40–49 1.00 (Referent)
50–59 1.133(0.848–1.515) 0.712 0.399
60–69 1.403(1.023–1.924) 4.419 0.036
70– 1.221 (0.770–1.938) 0.719 0.396
Gender Female 1.00 (Referent)
Male 1.011(0.802–1.273) 0.008 0.928
Residence Rural 1.00 (Referent)
Urban 1.368(1.021–1.834) 4.398 0.036
Education Primary school and below 1.00 (Referent)
Junior middle school 1.252(0.916–1.713) 1.987 0.159
Senior middle school 1.963(1.305–2.953) 10.487 0.001
College and above 2.325(1.447–3.734) 12.162 <0.001
Overweight or obesity No 1.00 (Referent)
Yes 1.881(1.499–2.359) 29.850 <0.001
Hypertension No 1.00 (Referent)
Have 1.751(1.339–2.289) 16.787 <0.001
Fruit consumption ≤2d/w 1.00 (Referent)
3-4d/w 0.883(0.445–1.753) 0.127 0.722
≥5d/w 0.319(0.134–0.759) 6.678 0.010
Diabetes mellitus No 1.00 (Referent)
Have 1.727(1.305–2.286) 14.621 <0.001
Personal history of coronary heart disease No 1.00 (Referent)
Yes 2.595(1.864–3.613) 31.878 <0.001
Personal history of stroke No 1.00 (Referent)
Yes 2.176(1.552–3.051) 20.314 <0.001
Method: Enter: Age, Gender, Residence; Forward-Conditional: Education, Overweight or obesity, Hypertension, Diabetes mellitus, Fruit consumption, Smoking, Alcohol
consumption, Lack of exercise, Personal history of stroke, Personal history of coronary heart disease, Family history of coronary heart disease, Family history of stroke
Abbreviations: OR odds ratio, CI confidence interval
Table 6 Multivariate logistic regression analyses on influence factors for treatment of dyslipidemia
Category Subcategory Fully adjusted OR (95% CI) Wald χ2 value p value
Age(years) 40–49 1.00 (Referent)
50–59 1.098(0.627–1.922) 0.107 0.744
60–69 0.892(0.492–1.615) 0.143 0.705
70– 1.134(0.494–2.601) 0.088 0.767
Gender Female 1.00 (Referent)
Male 0.769(0.500–1.182) 1.435 0.231
Residence Rural 1.00 (Referent)
Urban 0.827(0.537–1.272) 0.750 0.386
Personal history of coronary heart disease No 1.00 (Referent)
Yes 2.021(1.183–3.453) 6.634 0.010
Personal history of stroke No 1.00 (Referent)
Yes 1.743(1.002–3.032) 3.873 0.049
Method: Enter: Age, Gender, Residence; Forward-Conditional: Personal history of stroke, Personal history of coronary heart disease, Family history of coronary
heart disease
Abbreviations: OR odds ratio, CI confidence interval
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hypertension, or diabetes mellitus were at a higher risk
of dyslipidemia; also these people were more likely to be
aware of their condition. However, this did not increase
the likelihood of treatment and control of dyslipidemia.
Subjects living in urban areas and having higher educa-
tional level tended to be more aware of their dyslipid-
emia condition. Our study also suggests that subjects
with personal history of coronary heart disease were
most likely to be aware of, treat, and control their dyslip-
idemia condition; also subjects with personal history of
stroke were more likely to be aware of and treat their
dyslipidemia condition, but it didn’t mean well control
of their dyslipidemia. Overweight or obesity and lack of
exercise were also associated with poor dyslipidemia
control.
The first national study on serum lipids was part of
the China National Nutrition and Health Survey per-
formed in 2002 by China’s Center for Disease Control
and Prevention [17], which showed that the prevalence
of dyslipidemia in Chinese adults aged 18 and over was
18.6%, with 17.0, 22.9, and 23.4% in the age groups of
18–44, 45–59, and over 60 years old, respectively. In this
representative sample of northeast Chinese adults aged
40 years and over of our study, the overall prevalence of
dyslipidemia was 62.1%, with 58.6%, 64.4%, 65.7%, 63.3%
in the age groups of 40–49, 50–59, 60–69, and over
70 years old, respectively. These prevalence rates in each
age group over 40 years were significantly higher than
data reported by the China National Survey of Chronic
Kidney Disease Working Group, conducted from January
2007 to October 2010 [18, 19]. The cross-sectional survey
covered 13 provinces but did not contain any provinces in
northeast China, reporting that the adjusted prevalence of
dyslipidemia in Chinese adults in the age groups of 40–49,
50–59, 60–69, and over 70 years old was 43.6, 46.8, 45.3,
and 42.9%, respectively, for males, and 23.5, 39.9, 50.0,
and 46.6%, respectively, for females. Our study also
showed that high triglyceride was the most prevalent form
of dyslipidemia in northeast Chinese adults aged 40 years
and over, followed by high total cholesterol (the preva-
lence of high total cholesterol, triglyceride, low-density
lipoprotein cholesterol, and low high-density lipoprotein
cholesterol were 33.5, 43.9, 0.6, and 8.8%, respectively).
This was consistent with the overall pooled analysis,
including thirty-eight studies on the epidemiology of
dyslipidemia in Chinese adults [13]; however, this was
different from many other national cross-sectional
studies [18, 20, 21], in which low high-density lipo-
protein cholesterol or high low-density lipoprotein
cholesterol was the major type of dyslipidemia. In
addition to the differences in methodology and popu-
lation demography, local climate conditions, dietary
habits, and sedentary lifestyles might contribute to
the high prevalence of dyslipidemia [22], especially
high triglyceride and high total cholesterol in the
northeast Chinese adults aged 40 years and over. Jilin
Province, located in the center of northeast China,
has a temperate continental monsoon climate. The
cold climate leads to a deficiency of fresh fruits and
vegetables; thus, people eat relatively more animal fat
and fewer fresh vegetables and fruits. This diet leads
to a high prevalence of high triglyceride and total
cholesterol. Moreover, the cold weather limits people’s
outdoor physical activity during the long winter,
Table 7 Multivariate logistic regression analyses on influence factors for control of dyslipidemia
Category Subcategory Fully adjusted OR (95% CI) Wald χ2 value p value
Age(years) 40–49 1.00 (Referent)
50–59 0.544(0.264–1.123) 2.707 0.100
60–69 0.830(0.408–1.687) 0.266 0.606
70– 1.174(0.458–3.013) 0.112 0.738
Gender Female 1.00 (Referent)
Male 1.345(0.787–2.299) 1.178 0.278
Residence Rural 1.00 (Referent)
Urban 0.640(0.376–1.091) 2.692 0.101
Overweight or obesity No 1.00 (Referent)
Yes 0.404(0.235–0.695) 10.720 0.001
Lack of exercise No 1.00 (Referent)
Yes 0.423(0.215–0.830) 6.264 0.012
Personal history of coronary heart disease No 1.00 (Referent)
Yes 2.056(1.083–3.905) 4.852 0.028
Method: Enter: Age, Gender, Residence; Forward-Conditional: Overweight or obesity, Diabetes mellitus, Fruit consumption, Lack of exercise, Personal history of
coronary heart disease, Family history of coronary heart disease
Abbreviations: OR odds ratio, CI confidence interval
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consequently increasing the risk of overweight or
obesity and related metabolic abnormalities. Elevated
triglycerides [10] and high total cholesterol levels [8],
as predictive of cardiovascular risk, have been well-
established. Therefore, lowering triglyceride and total
cholesterol levels is the primary and urgent target for
cardiovascular disease prevention in northeast China.
In the present study, factors associated with the preva-
lence of dyslipidemia included increasing age, living in
urban regions, having personal or family history of coron-
ary heart disease, and family history of dyslipidemia. Our
study also found that overweight or obesity and lack of
exercise were associated with an increased the risk of
dyslipidemia. In addition, people with underlying chronic
diseases, such as hypertension, or diabetes mellitus were at
a higher risk of dyslipidemia. These results were partly
consistent with many previous studies [18, 20, 21, 23]. It
may reflect that factors associated with dyslipidemia and
the consequences of dyslipidemia (such as overweight or
obesity) are similar among different ethnicities. This sug-
gests that people with underlying chronic diseases, such as
obesity, hypertension, and diabetes mellitus are at a higher
risk of developing dyslipidemia and should be more care-
fully monitored and managed.
Dyslipidemia is one of the most important independ-
ent modifiable risk factors for cardiovascular disease in
both Western [24, 25] and Asian [26, 27] populations.
Raising the awareness, treatment and control rate of dys-
lipidemia has a positive impact on the primary and
secondary prevention of cardiovascular disease. In 2010,
Li et al. [28] reported that the awareness rate of dyslipid-
emia among Chinese adults aged 45–59 and over
60 years old was 16.75 and 18.74%, respectively. The
treatment rate was 10.73 and 12.05% in the correspond-
ing age groups, and the control rates were was 5.49 and
6.94%, respectively. Our study showed that the aware-
ness, treatment, and control rate of dyslipidemia in
northeast Chinese adults aged 40 years and over were
14.4, 33.9, and 19.9%, respectively. These rates were sig-
nificantly higher than the China National Diabetes and
Metabolic Disorders Study [29] conducted from June
2007 to May 2008, in which the awareness, treatment,
and control of borderline high or high total cholesterol
was 11.0, 5.1, and 2.8%, respectively. This showed that
with the great importance attached to early screening,
health education, and intervention therapy in recent
years, people’s awareness and prevention methods for
chronic disease are being improved. Even so, these rates
are still far below those from Canada and the US [30]. In
the current study, we also found that lipid-lowering
drugs alone would not solve the problem of dyslipidemia
control completely. Even in those who were receiving
treatment for dyslipidemia, only 19.9% participants con-
trol their serum lipids at normal levels. In addition to
increasing rates of statin prescription and lifestyle inter-
vention in the patients with severe dyslipidemia [31–33],
we should popularize the awareness of nutraceuticals
and functional food ingredients in influencing dyslipid-
emia in the public. Scicchitano P et al.[34] suggested
that nutraceutical and functional food ingredients, such
as resveratrol, polyphenols, proanthocyanidins, fish oil,
etc., can be adopted in the common pharmacological
treatments for dyslipidemia, such as statin therapy. They
can positively influence lipid profile by combining the
effects of drug therapy. What’s more, they can be con-
sidered as an alternative therapeutic option in situations
where statins cannot be used because of intolerance.
In this study, we found that subjects with a personal
history of coronary heart disease or stroke were more
likely to be aware of and treat their dyslipidemia condi-
tion. Moreover, subjects with personal history of coronary
heart disease were more inclined to control their serum
lipids at normal levels, while this was not found in the
subjects with personal history of stroke. Previous re-
searches [35–37] have shown that those who had a cardio-
vascular event before often become more focused on their
health, being particularly concerned about cardiovascular
disease risk factors, including dyslipidemia, and these pa-
tients always were more probably to engage in and comply
with lipid-lowering drugs or lifestyle intervention for dys-
lipidemia. Our study also revealed that those highly edu-
cated usually had a higher rate of awareness than those
with low education levels. This finding was consistent with
several other studies [14, 38–41]. Previous report has sug-
gested that education is the best socioeconomic status
index and predicts awareness of risk factors for cardiovas-
cular disease [42]. The higher the level of education
attained by an individual, the more likely they are to
express increased awareness about health conditions,
including dyslipidemia.
This population-based cross-sectional epidemiologic
study was conducted in a large representative sample of
northeast Chinese adults aged 40 and over. The data
were taken from the 2015–16 Stroke Screening and
Prevention Program in northeast China. Standard pro-
tocols and instruments designed by the Stroke Screen-
ing and Prevention Program of the National Health and
Family Planning Commission of China, along with
strict training processes for data collection, were used
to ensure the high quality of the data. In addition,
standard laboratory methods for the measurement of
serum lipids were used, and the sample was uniformly
measured by Changchun Kingmed Center for Clinical
Laboratory Co., Ltd. For all the aforementioned rea-
sons, our study provides the most reliable and up-to-
date information on the prevalence, awareness, treatment,
and control of dyslipidemia in adults aged 40 and over in
northeast China.
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However, the findings of our present study should be
interpreted with an understanding of the following limi-
tations. First, as these findings were derived from a
cross-sectional study without a strict follow-up design,
and the prevalence, awareness, treatment, and control of
dyslipidemia were based on questionnaire and measure-
ments taken by a single visit, the results are prone to be
affected by the recall bias and unmeasured confounding.
Second, the definition of dyslipidemia in our study was
based on Chinese guidelines on prevention and treat-
ment of dyslipidemia in adults; therefore, the compari-
son between our results and those from other countries
should be carefully made. Finally, no causal relationships
could be precisely delineated for the properties of the
cross-sectional study.
Conclusions
In conclusion, we have identified a high prevalence of
dyslipidemia among adults aged 40 years and over in
northeast China, especially in the urban areas. Our
cross-sectional study showed that high triglycerides and
high total cholesterol are two major types of dyslipid-
emia in northeast China. However, the awareness, treat-
ment, and control rates of dyslipidemia are far from the
desirable levels. Renewed efforts taking influence factors
into account are needed to lower the prevalence of dys-
lipidemia and increase the awareness, treatment, and
control rates of dyslipidemia. These efforts includes
strengthening the primary care system, promotion of a
healthy lifestyle, and energetically improve people’s edu-
cational degrees.
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